Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL

VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL

November 04, 2023

a231103_00.png

Previous: VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA

Next: VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat